The potential role of chemokines and inflammatory cytokines in periodontal disease progression

Clinical Infectious Diseases

Volumn 28, Issue 3, 1999, Pages 482-490

  Graves, D T ^a,b  

^a BOSTON UNIVERSITY   (United States)

^b BOSTON UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CHEMOKINE; CYTOKINE; INTERLEUKIN 1; MONOCYTE CHEMOTACTIC PROTEIN 1; TUMOR NECROSIS FACTOR;

BONE ATROPHY; CONFERENCE PAPER; DEFENSE MECHANISM; DISEASE COURSE; INFLAMMATION; MEDIATOR RELEASE; PERIODONTAL DISEASE; PERIODONTITIS; PRIORITY JOURNAL; PROTECTION; TISSUE INJURY; WOUND HEALING;

EID: 0032974306     PISSN: 10584838     EISSN: None     Source Type: Journal    
DOI: 10.1086/515178     Document Type: Conference Paper

References (82)

1. 1. Oppenheim J, Zachariae C, Mukaida N, Matsushima K. Properties of the novel proinflammatory supergene "intercrine" cytokine family. Ann Rev Immunol 1991;9:617-48.
2. 2. Baggiolini M. Chemokines and leukocyte traffic. Nature 1998;392:565-8.
3. 3. Ward SG, Westwick J. Chemokines: understanding their role in T-lymphocyte biology. Biochem J 1998;1:333:457-70.
4. 4. Van Damme JPP, Lenaerts J, Opdenaker G. Structural and functional identification of two human tumor-derived monocyte chemotactic proteins (MCP-2 and MCP-3) belonging to the chemokine family. J Exp Med 1992;176:59-65.
5. 5. Opdenakker GFG, Fiten P, Proost P, Van Damme J. Human monocyte chemotactic protein-3 (MCP-3): molecular cloning of the cDNA and comparison with other chemokines. Biochem Biophys Res Commun 1993;191:535-42.
6. 6. Schall T, Bacon K. Chemokines, leukocyte trafficking, and inflammation. Curr Opin Immunol 1994;6:865-73.
7. 7. Bischoff S, Krieger M, Brunner T, et al. RANTES and related chemokines activate human basophil granulocytes through different G protein-coupled receptors. Eur J Immunol 1993;23:761-77.
8. 8. Miller MD, Hata S, De Waal Malefyt R, Krangel MS. A novel polypeptide secreted by activated human T lymphocytes. J Immunol 1989;143:2907-16.
9. 9. Burd PR, Rogers HW, Gordon JR, et al. Interleukin-3 dependent and independent mast cells stimulated with IgE and antigen express multiple cytokines. J Exp Med 1989;170:245-57.
10. + T lymphocytes. FASEB J 1994;8:1055-60.
11. 11. Schall T, Toy K, Goeddel D. Selective attraction of monocytes and T-lymphocytes of the memory phenotype by cytokine RANTES. Nature 1990;347:669-71.
12. 12. Broxmeryer HE, Sherry B, Lu L, et al. Myelopoietic enhancing effects of murine macrophage inflammatory proteins 1 and 2 on colony formation in vitro by murine and human bone marrow granulocyte/macrophage progenitor cells. J Exp Med 1989;170:1583-94.
13. 13. Valente A, Graves D, Vialle-Valentin C, Delgado R, Schwartz C. Purification of a monocyte chemotactic factor secreted by nonhuman primate vascular cells in culture. Biochemistry 1988;27:4162-8.
14. 14. Yoshimura T, Robinson E, Tanaka S, Apella E, Kuratsu J, Leonard E. Purification and amino acid analysis of two human glioma-derived monocyte chemoattractants. J Exp Med 1989;169:1449-59.
15. 15. Matsushima K, Larsen CG, DuBois GC, JJ O. Purification and characterization of a novel monocyte chemotactic and activating factor produced by a human myelomonocytic cell line. J Exp Med 1989:1485-90.
16. 16. Jiang Y, Tabak LA, Valente AJ, Graves DT. Initial characterization of the carbohydrate structure of MCP-1. Biochem Biophys Res Commun 1991; 178:1400-4.
17. 17. Rollins B. Monocyte chemoattractant protein 1: a potential regulator of monocyte recruitment in inflammatory disease. Mol Med Today 1996; 2:198-204.
18. 18. Rollins B, Walz A, Baggiolini M. Recombinant human MCP-1/JE induces chemotaxis, calcium flux and the respiratory burst in human monocytes. Blood 1991;78:1112-6.
19. 19. Jiang Y, Beller D, Frendl G, Graves DT. Monocyte chemoattractant protein-1 regulates adhesion molecule expression and cytokine production in human monocytes. J Immunol 1992;148:2423-8.
20. 20. Cushing SFA. Monocytes may amplify their recruitment into inflammatory lesions by inducing monocyte chemotactic protein. Arterioscler Thromb Vasc Biol 1992;12:78-82.
21. 21. Yla-Herttuala S, Lipton A, Rosenfeld M, et al. Expression of monocyte chemoattractant protein 1 in macrophage-rich areas of human and rabbit atherosclerotic lesions. Proc Natl Acad Sci USA 1991;88:5252-6.
22. 22. Yu X, Dluz S, Graves DT, et al. Elevated expression of monocyte chemoattractant protein-1 by vascular smooth muscle cells in hypercholesterolemic primates. Proc Natl Acad Sci USA 1992;89:6953-7.
23. 23. Yu X, Barnhill R, Graves DT. Expression of monocyte chemoattractant protein-1 (MCP-1) in delayed type hypersensitivity reactions in the skin. Lab Invest 1994;71:226-35.
24. 24. Graves DT, Barnhill R, Galanopoulos T, Antoniades H. Expression of monocyte chemoattractant protein-1 in human melanoma in vivo. Am J Pathol 1992;140:9-14.
25. 25. Villiger P, Terkeltaub R, Lotz M. Production of monocyte chemoattractant protein-1 by inflamed synovial tissue and cultured synoviocytes. J Immunol 1992;149:722-7.
26. 26. Yu X, Graves DT. Fibroblasts, mononuclear phagocytes and endothelial cells express MCP-1 in inflamed human gingiva. J Periodontol 1995; 66:80-8.
27. 27. Rahimi P, Wang C, Stashenko P, Lee S, Lorenzo J, Graves DT. MCP-1 expression and monocyte recruitment in osseous inflammation. Endocrinology 1995;136:2752-9.
28. 28. Zachariae C, Anderson A, Thompson H, et al. Properties of monocytic chemotactic and activating factor (MCAF) purified from a human fibrosarcoma cell line. J Exp Med 1990;171:2177-82.
29. 29. Yu X, Antoniades H, Graves DT. Expression of monocyte chemoattractant protein-1 in human inflamed gingival tissues. Infect Immun 1993;61:4622-8.
30. 30. Springer T. Traffic signals for lymphocyte recirculation and leukocyte immigration: the multlistep paradigm. Cell 1994;76:301-14.
31. 31. Wang C, Stashenko P. The role of interleukin-1 alpha in the pathogenesis of periapical bone destruction in a rat model system. Oral Microbiol Immunol 1993;8:50-6.
32. 32. Marcus R. Normal and abnormal bone remodeling in man. Ann Rev Med 1987;38:129-41.
33. 33. Mundy G. Inflammatory mediators and the destruction of bone. J Periodontal Res 1991;26:213-7.
34. 34. Gowen M, Wood D, Ihrie E, McGuire M, Russell R. An interleukin-1 like factor stimulates bone resorption in vitro. Nature 1983;306:378-80.
35. 35. Zhu J, Valente A, Lorenzo J, Carnes D, Graves DT. Expression of monocyte chemoattractant protein 1 in human osteoblastic cells stimulated by proinflammatory mediators. J Bone Miner Res 1994;999:1123-30.
36. 36. Williams, SR, Jiang Y, Cochran D, Dorsam G, Graves DT. Regulated expression of monocyte chemoattractant protein-1 in normal human osteoblastic cells. Am J Physiol 1992;32:C194-9.
37. 37. Filder IJ. Macrophages and metastasis-α biological approach to cancer therapy. Cancer Res 1985;45:XXX-XX.
38. 38. Hibbs JB, Chapman HA, Weinberg JB. The macrophage as an antineoplastic surveillance cell. J Reticuloendothel Soc 1978;24:549-70.
39. 39. Mantovani A. Tumor associated macrophages. Curr Opin Immunol 1989; 2:689-92.
40. 40. Gauchi CL, Alexander P. The macrophage content of some human tumors. Cancer Lett 1975;1:29-32.
41. 41. Loeffler DA, Keng PC, Baggs RB, Lord EM. Lymphocyte infiltration and cytotoxicity under hypoxic conditions in the EMT16 mouse mammary tumor. Int J Cancer 1990;45:462-7.
42. 42. Munzarova MJK. Is cancer a macrophage-mediated autoaggressive disease? Lancet 1987:952-4.
43. 43. Mantovani A. Tumor associated leukocytes: pathophysiology and therapeutic applications. Austin, Texas: RG Landes, 1994.
44. 44. Nathan C. Secretory products of macrophages. J Clin Invest 1987;79:319-26.
45. 45. Gordon S. Biology of the macrophage. J Cell Sci 1986;4:267-86.
46. 46. Acero R, Polentarutti N, Bottazzi B, et al. Effect of hydrocortisone on the macrophage content, growth and metastasis of transplanted murine tumors. Int J Cancer 1984;33:95-105.
47. 47. McBride W. Phenotype and functions of intratumoral macrophages. Biochem Biophys Acta 1986;865:27-41.
48. 48. Stephens T, Currie G, Peacock J. Repopulation of gamma-irradiated Lewis lung carcinoma by malignant cells and host macrophage progenitors. Br J Cancer 1978;38:573-82.
49. 49. Bottazzi B, Polentarutti N, Acero R. Regulation of the macrophage content of neoplasms by chemoattractants. Science 1982;220:210-2.
50. 50. Rollins BJ, Sunday ME. Suppression of tumor formation in vivo by expression of the JE gene in malignant cells. Mol Cell Biol 1991;11:3125-31.
51. 51. Graves DT, Jiang Y, Williamson M, Valente A. Identification of monocyte chemotactic activity produced by malignant cells. Science 1989;245:1490-3.
52. 52. Botazzi BGW, Colotta F, Mantovani A. Monocyte chemotactic cytokine gene transfer modulates macrophage infiltration growth and susceptibility to IL-2 therapy of a murine melanoma. J Immunol 1992;148:1280-5.
53. 53. Yamashiro TTM, Nishi T, Kuratsu J-I, Yoshimura T, Ushi Y, Takahashi K. Tumor-derived monocyte chemoattractant protein-1 induces intratumoral infiltration of monocyte-derived macrophage subpopulation in transplanted rat tumors. Am J Pathol 1994;145:856-67.
54. 54. Zhang L, Yoshimura T, Graves DT. Antibody to Mac-1 or monocyte chemoattractant protein-1 inhibits monocyte recruitment and promotes tumor growth. Lab Invest 1997;6:579-90.
55. 55. Zhang L, Yoshimura T, Graves DT. Antibody to Mac-1 or monocyte . chemoattractant protein-1 inhibits monocyte recruitment and promotes tumor growth. J Immunol 1997;158:4855-61.
56. 56. Dinarello C. Interleukin-1 and interleukin-1 antagonism. Blood 1991;77:1627-52.
57. 57. Beutler B, Van Huffel C. Unraveling function in the THF ligand and receptor families. Science 1994;264:667-8.
58. 58. Peschon JJ, Torrance DS, Stocking K, et al. TNF receptor-deficient mice reveal divergent roles for p55 and p75 in several models of inflammation. J Immunol 1998;160:943-52.
59. 59. Rothe J, Lesslauer W, Lotscher H, et al. Mice lacking the tumor necrosis factor receptor 1 are resistant to TNF-mediated toxicity but highly susceptible to infection by Listeria monocytogenes. Nature 1993;364:798-802.
60. 60. Fantuzzi G, Zheng H, Faggioni R, et al. Effect of endotoxin in IL-1 beta-deficient mice. J Immunol 1996;157:291-6.
61. 61. Zheng H, Fletcher D, Kozak W, et al. Resistance to fever induction and impaired acute-phase response in interleukin-1β-deficient mice. Immunity 1995;3:9-19.
62. 62. Arend W. Interleukin-1 receptor antagonist. Adv Immunol 1993;54:167-227.
63. 63. Seckinger P, Klein-Nulend J, Alander C, Thompson RC, Dayer JM, Raisz LG. Natural and recombinant human IL-1 receptor antagonists block the effects of IL-1 on bone resorption and prostaglandin production. J Immunol 1990;145:4181-4.
64. 64. Lebsack ME, Paul CC, Boedow DC, et al. Subcutaneous IL-1 receptor antagonist in patients with rheumatoid arthritis. Arthritis Rheum 1991;34:S45.
65. 65. Cominelli F, Nast C, Clark B, et al. Interleukin 1 (IL-1) gene expression, synthesis, and effect of specific IL-1 receptor blockade in rabbit immune complex colitis. J Clin Invest 1990;86:972-80.
66. 66. McCarthy PJ, Abhyankar S, Neben S, et al. Inhibition of interleukin-1 by an interleukin-1 receptor antagonist prevents graft-versus-host disease. Blood 1991;78:1915-8.
67. 67. Mullarkey MF, Leiferman KM, Peter MS, et al. Human cutaneous allergic late-phase response is inhibited by soluble IL-1 receptor. J Immunol 1994;152:2033-41.
68. 68. Ulich T, Yi E, Yin S, Smith C, Remick D. Intratracheal administration of endotoxin and cytokines. VII: The soluble interleukin-1 receptor and the soluble tumor necrosis factor receptor II (p80) inhibit acute inflammation. Clin Immunol Immunopathol 1994;72:137.
69. 69. Windsor A, Walsh C, Mullen P, et al. Tumor necrosis factor-alpha blockade prevents neutrophil CD18 receptor upregulation and attenuates acute lung injury in porcine sepsis without inhibition of neutrophil oxygen radical generation. J Clin Invest 1993;91:91:1459.
70. 70. Haak-Frendscho M, Marsters S, Mordenti J, et al. Inhibition of TNF by a TNF receptor immunoadhesion. Comparison to anti-TNF monoclonal antibody. J Immunol 1994;152:1347.
71. 71. Hofman C, Lorenz K, Brathwaite S, Colca J. Altered gene expression for tumor necrosis factor-alpha and its receptors during drug and dietary modulation of insulin resistance. Endocrinology 1994;134:264-70.
72. 72. Page R. The role of inflammatory mediators in the pathogenesis of periodontal disease. J Periodontal Res 1991;26:230-42.
73. 73. Assuma R, Oates T, Cochran D, Amar S, Graves DT. IL-1 and TNF antagonists inhibit the inflammatory response and bone loss in experimental periodontitis. J Immunol 1997;160:403-9.
74. 74. Kimble R, Matayoshi A, Vannice J, Kung V, Williams C, Pacifici R. Simultaneous block of interleukin-1 and tumor necrosis factor is required to completely prevent bone loss in the early postovariectomy period. Endocrinology 1995;136:3054-61.
75. 75. Williams RC, Jeffcoat MK, Kaplan ML, Goldhaber P, Johnson HG, Wechter WJ. Flurbiprofen: a potent inhibitor of alveolar bone resorption in beagles. Science 1985;227:640.
76. 76. Masada MP, Persson R, Kenny JS, Lee SW, Page RC, Allison AC. Measurement of interleukin-1 alpha and -1 beta in gingival crevicular fluid: implications for the pathogenesis of periodontal disease. J Periodontal Res 1990;25:156-63.
77. 77. Stashenko P, Jandinski JJ, Fujiyoshi P, Rynar J, Socransky SS. Tissue levels of bone resorptive cytokines in periodontal disease. J Periodontol 1991;62:504-9.
78. 78. Honig J, Rordorf-Adam C, Siegmund C, Weidemann W, Erard F. Increased interleukin-1 beta (IL-1 beta) concentration in gingival tissue from periodontitis patients. J Periodontal Res 1989;24:362-7.
79. 79. Jandinski JJ, Stashenko P, Feder LS, et al. Localization of interleukin-1 beta in human periodontal tissue. J Periodontol 1991;62:36-43.
80. 80. Smith MA, Braswell LD, Collins JG, et al. Changes in inflammatory mediators in experimental periodontitis in the rhesus monkey. Infect Immun 1993;61:1453-9.
81. 81. Lindemann RA, Economou JS, Rothermel H. Production of interleukin-1 and tumor necrosis factor by human peripheral monocytes activated by periodontal bacteria and extracted lipopolysaccharides. J Dental Res 1988;67:1131-5.
82. 82. Rossomando EF, Kennedy JE, Hadjimichael J. Tumor necrosis factor alpha in gingival crevicular fluid as a possible indicator of periodontal disease in humans. Arch Oral Biol 1990;35:431-4.